DOPTELET
LOE Approachingavatrombopag maleate
NDAORALTABLETPriority Review
Approved
May 2018
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
DOPTELET (avatrombopag maleate) is bioavailable, small molecule tpo receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPTELET (avatrombopag maleate) is an oral, bioavailable small-molecule TPO receptor agonist that stimulates megakaryocyte proliferation and platelet production without competing with endogenous TPO. It is indicated for patients with thrombocytopenia requiring platelet support, typically in chronic immune thrombocytopenia (ITP) and pre-procedural settings.
$96MPart D
LOE ApproachingStable
9mo to LOEProduct is approaching loss of exclusivity in ~0.8 years, indicating contracted team size and transition planning for brand teams.
Mechanism of Action
bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Started Feb 2022
199 enrolled
Immune ThrombocytopeniaITP
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.